TrimMedium
MRSH is in Stage 3 distribution following a decisive support failure, reinforcing a bearish medium-term bias. Short-term conditions are extremely oversold and price is extended below the 9/20 EMAs, making immediate selling unfavorable; defer execution by trimming into rallies toward the EMA band or prior support-turned-resistance.
- ↑Q2 2026 revenue up 6% YoY to $7.4B; adjusted EPS +9% to $2.96.
- ↑H1 share buybacks of $1.5B underline disciplined capital returns.
- ↓Pricing pressure in property & casualty likely to compress revenue growth.
Full analysis →